ELDN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.202

-78.67%

-0.250

+212.5%

-0.257

+97.44%

Estimates Revision

The market is revising No Change the revenue expectations for Eledon Pharmaceuticals, Inc. (ELDN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -41.95%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-41.95%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast ELDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELDN is 7.75 USD with a low forecast of 4.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

7.75

High

10.00

Current: 0.000

Low

4.00

Averages

7.75

High

10.00

Guggenheim

Buy

maintain

$9 -> $8

2025-11-18

Reason

Guggenheim

Price Target

$9 -> $8

2025-11-18

maintain

Buy

Reason

Guggenheim lowered the firm's price target on Eledon Pharmaceuticals to $8 from $9 and keeps a Buy rating on the shares following the Q3 report last week. In addition to "routine incrementally positive adjustments," the firm is also incorporating the dilution from the recent fund raising, the analyst tells investors.

Craig-Hallum

NULL -> Buy

initiated

$12

2025-07-25

Reason

Craig-Hallum

Price Target

$12

2025-07-25

initiated

NULL -> Buy

Reason

Craig-Hallum initiated coverage of Eledon Pharmaceuticals with a Buy rating and $12 price target.

Craig-Hallum

initiated

$12

2025-07-25

Reason

Craig-Hallum

Price Target

$12

2025-07-25

initiated

Reason

As previously reported, Craig-Hallum initiated coverage of Eledon Pharmaceuticals with a Buy rating and $12 price target. Eledon is developing tegoprubart to address the need for a new SOC in immunosuppression for kidney transplant patients, as current therapies cause kidney damage as a side effect, contributing to kidney graft failure after 10-15 years. The firm notes Tegoprubart's advantages support its potential to be the new SOC for kidney transplantation, which is a multi-billion dollar market opportunity, and it has broad utility in other organ transplant settings. Craig-Hallum sees opportunity for significant share appreciation with upcoming data catalysts in kidney transplantation including a Phase Ib update at WTC on August 6th, with readthrough to the Phase II topline readout in November, which represents a major de-risking event.

H.C. Wainwright

Yi Chen

initiated

2025-06-19

Reason

H.C. Wainwright

Yi Chen

Price Target

2025-06-19

initiated

Reason

H.C. Wainwright analyst Yi Chen assmed coverage of Eledon Pharmaceuticals with a Buy rating and $9 price target. Eledon is a clinical-stage biotechnology company focused on the development of an antibody targeting the CD40 ligand to prevent the rejection of transplanted organs and to treat neuroinflammation, the analyst tells investors in a research note. The firm says interim results from the Phase 1b trial demonstrated the company's lead candidate tegoprubart is generally safe and well tolerated in patients undergoing de novo kidney transplantation.

Valuation Metrics

The current forward P/E ratio for Eledon Pharmaceuticals Inc (ELDN.O) is -1.69, compared to its 5-year average forward P/E of -2.14. For a more detailed relative valuation and DCF analysis to assess Eledon Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.14

Current PE

-1.69

Overvalued PE

-0.72

Undervalued PE

-3.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.13

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

5.78

Undervalued EV/EBITDA

-8.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 138.83% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ELDN News & Events

Events Timeline

No data

News

3.5

2025-12-31PRnewswire

Avant Technologies Achieves 83% Insulin Independence Rate, Driving Investment Shift

3.5

2025-12-31Newsfilter

Avant Technologies Achieves 83% Insulin Independence Rate, Driving Metabolic Disease Investment

2.0

2025-12-18NASDAQ.COM

Biotech Sector Sustains After-Hours Trading Gains

People Also Watch

Frequently Asked Questions

What is Eledon Pharmaceuticals Inc (ELDN) stock price today?

The current price of ELDN is 1.73 USD — it has increased 0 % in the last trading day.

What is Eledon Pharmaceuticals Inc (ELDN)'s business?

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

What is the price predicton of ELDN Stock?

What is Eledon Pharmaceuticals Inc (ELDN)'s revenue for the last quarter?

Eledon Pharmaceuticals Inc revenue for the last quarter amounts to -19.07M USD, decreased -7.02 % YoY.

What is Eledon Pharmaceuticals Inc (ELDN)'s earnings per share (EPS) for the last quarter?

Eledon Pharmaceuticals Inc. EPS for the last quarter amounts to -14477000.00 USD, increased 23.01 % YoY.

What changes have occurred in the market's expectations for Eledon Pharmaceuticals Inc (ELDN)'s fundamentals?

How many employees does Eledon Pharmaceuticals Inc (ELDN). have?

Eledon Pharmaceuticals Inc (ELDN) has 31 emplpoyees as of January 10 2026.

What is Eledon Pharmaceuticals Inc (ELDN) market cap?

Today ELDN has the market capitalization of 129.81M USD.